Cargando…
The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor
BACKGROUND: The phosphatidylinositol 3 kinase (PI3K) signalling pathway is frequently altered in human cancer and a promising therapeutic target. AZD8186 (AstraZeneca) is a PI3Kβ/δ inhibitor, currently in phase 1 clinical trials. (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET)...
Autores principales: | Maynard, Juliana, Emmas, Sally-Ann, Blé, Francois-Xavier, Barjat, Hervé, Lawrie, Emily, Hancox, Urs, Oakes, Deborah, Polanska, Urszula M., Barry, Simon T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980858/ https://www.ncbi.nlm.nih.gov/pubmed/27515445 http://dx.doi.org/10.1186/s13550-016-0220-9 |
Ejemplares similares
-
The use of (18)F-Fluoro-deoxy-glucose positron emission tomography ((18)F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor
por: Maynard, Juliana, et al.
Publicado: (2017) -
(18)F-fluorodeoxyglucose and (18)F-flumazenil positron emission tomography in patients with refractory epilepsy
por: Hodolic, Marina, et al.
Publicado: (2016) -
Diagnosis of prostatitis by 18-F-fluorodeoxyglucose positron emission tomography
por: Ho, Thien Anh, et al.
Publicado: (2009) -
Thoracic positron emission tomography: (18)F-fluorodeoxyglucose and beyond
por: Jaykel, Timothy J., et al.
Publicado: (2020) -
Neurolymphomatosis detected by (18)F‐fluorodeoxyglucose‐positron emission tomography
por: Hori, Yoshikazu, et al.
Publicado: (2020)